Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma

Next Previous
X
Search
Trial Profile

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SYMPATICO
  • Sponsors Pharmacyclics

    • Most Recent Events

    • 01 Jul 2024 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2024 Results reporting efficacy and safety of Ibr+Ven in pts with TP53 mutations across cohorts, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2023 Primary endpoint has been met. (progression-free survival (PFS) by investigator (INV) assessment using Lugano criteria), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top